EA
CTMX icon

Emerald Acquisition’s CytomX Therapeutics CTMX Stock Holding History

Emerald Acquisition’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$342K Sell
21,842
-21,842
-50% -$264K ﹤0.01% 2571
2016
Q2 		$446K Buy
+43,684
New +$498K ﹤0.01% 2517

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPI
Canaan Partners IX Menlo Park, California $87.5M AUM
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Emerald Acquisition's CTMX Position: Q3 2016 in Review

Emerald Acquisition reduced its CytomX Therapeutics (CTMX) stake by 50% in Q3 2016, selling an estimated $264K and leaving 21,842 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #2571.

Emerald Acquisition first reported a position in CTMX in Q2 2016 and has held it in 2 quarters since. The position peaked at $446K in Q2 2016. 62 funds tracked by Wall St. Rank hold CTMX as of Q3 2016.

  • Emerald Acquisition held 21,842 shares of CytomX Therapeutics worth $342K as of Q3 2016.
  • Emerald Acquisition sold 21,842 CytomX Therapeutics shares in Q3 2016, an estimated $264K.
  • CytomX Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2571 holding.
  • Emerald Acquisition first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's CytomX Therapeutics position peaked at $446K in Q2 2016.
  • 62 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.